Latest Insider Transactions at Biomarin Pharmaceutical Inc (BMRN)
This section provides a real-time view of insider transactions for Biomarin Pharmaceutical Inc (BMRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOMARIN PHARMACEUTICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOMARIN PHARMACEUTICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,073
-3.07%
|
$167,913
$81.0 P/Share
|
|
Mar 21
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,129
-8.82%
|
$496,449
$81.29 P/Share
|
|
Mar 16
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,287
-1.87%
|
$102,960
$80.72 P/Share
|
|
Mar 16
2022
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,560
-1.63%
|
$444,800
$80.72 P/Share
|
|
Mar 16
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,252
-1.77%
|
$100,160
$80.72 P/Share
|
|
Mar 16
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-1.5%
|
$46,560
$80.72 P/Share
|
|
Mar 16
2022
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,259
-1.55%
|
$180,720
$80.72 P/Share
|
|
Mar 15
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,418
-10.91%
|
$656,604
$78.27 P/Share
|
|
Mar 15
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,940
+13.4%
|
-
|
|
Mar 15
2022
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
38,306
-10.11%
|
$2,987,868
$78.27 P/Share
|
|
Mar 15
2022
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,280
+9.61%
|
-
|
|
Mar 15
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,290
-10.49%
|
$646,620
$78.27 P/Share
|
|
Mar 15
2022
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+12.26%
|
-
|
|
Mar 15
2022
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
920
-1.74%
|
$71,760
$78.27 P/Share
|
|
Mar 15
2022
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+17.25%
|
-
|
|
Mar 15
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,868
-4.58%
|
$145,704
$78.27 P/Share
|
|
Mar 15
2022
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+21.32%
|
-
|
|
Mar 15
2022
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
12,101
-7.65%
|
$943,878
$78.27 P/Share
|
|
Mar 15
2022
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
38,790
+19.7%
|
-
|
|
Mar 11
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-4.24%
|
$1,155,000
$77.81 P/Share
|
|
Mar 11
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+4.07%
|
$555,000
$37.46 P/Share
|
|
Mar 10
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-4.24%
|
$1,155,000
$77.57 P/Share
|
|
Mar 10
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+4.07%
|
$555,000
$37.46 P/Share
|
|
Mar 08
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,370
+12.56%
|
-
|
|
Mar 08
2022
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,370
+12.12%
|
-
|
|
Mar 08
2022
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
12,840
+9.72%
|
-
|
|
Mar 08
2022
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,780
+9.32%
|
-
|
|
Feb 28
2022
|
Dennis Slamon Director |
SELL
Open market or private sale
|
Direct |
6,396
-3.9%
|
$498,888
$78.35 P/Share
|
|
Feb 25
2022
|
Elaine J Heron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+9.54%
|
$314,500
$37.46 P/Share
|
|
Feb 03
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,072
-3.48%
|
$93,264
$87.77 P/Share
|
|
Jan 14
2022
|
V Bryan Lawlis Director |
SELL
Open market or private sale
|
Direct |
4,250
-15.06%
|
$369,750
$87.61 P/Share
|
|
Jan 14
2022
|
V Bryan Lawlis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,250
+13.09%
|
$157,250
$37.46 P/Share
|
|
Jan 13
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.62%
|
$435,000
$87.86 P/Share
|
|
Jan 13
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.59%
|
$185,000
$37.46 P/Share
|
|
Jan 12
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.62%
|
$445,000
$89.0 P/Share
|
|
Jan 12
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.59%
|
$185,000
$37.46 P/Share
|
|
Jan 03
2022
|
Mark J Alles Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+50.0%
|
-
|
|
Dec 21
2021
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
100
+0.03%
|
$8,900
$89.22 P/Share
|
|
Dec 16
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
6,000
-1.94%
|
$504,000
$84.68 P/Share
|
|
Dec 16
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+1.9%
|
$222,000
$37.46 P/Share
|
|
Dec 15
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
6,000
-1.94%
|
$492,000
$82.71 P/Share
|
|
Dec 15
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+1.9%
|
$222,000
$37.46 P/Share
|
|
Dec 10
2021
|
Jean Jacques Bienaime Director |
SELL
Bona fide gift
|
Direct |
700
-0.23%
|
-
|
|
Dec 01
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,500
-0.49%
|
$130,500
$87.22 P/Share
|
|
Oct 26
2021
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,739
-4.67%
|
$199,947
$73.6 P/Share
|
|
Oct 20
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+0.33%
|
$37,000
$37.46 P/Share
|
|
Sep 09
2021
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
50
+0.02%
|
$3,900
$78.77 P/Share
|
|
Aug 02
2021
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,518
-8.61%
|
$419,368
$76.69 P/Share
|
|
Jul 16
2021
|
Andrea Acosta GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
285
-1.55%
|
$22,230
$78.84 P/Share
|
|
Jun 29
2021
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
576
-1.84%
|
$47,808
$83.46 P/Share
|